A Clinical Study of PROSMAN in 140 Patients with BPH
Efficacy Conclusions
On completion of the study, following efficacy conclusions were made from Prosman on Benign prostate hyperplasia patients under study:
A significant decrease in IPSS score was observed after 4 weeks and on completion of treatment, All the patients reported decrease in IPPS score.
94% of the patients showed decrease in prostate volume. A total of 29.46% decrease in prostate volume was observed. The significant decrease was observed even after four weeks of treatment.
The decrease in serum PSA levels was 56%, which was statistically significant. 76% of the patients showed decrease in serum PSA levels on completion of treatment.
Safety Conclusions
On completion of the study, following safety conclusions were made:
No significant change in liver function tests (serum GOT, GPT & ALP activity) was observed.
No significant change in serum urea levels and serum creatinine levels was observed.
No significant change in hematological parameter was observed on completion of the treatment.
